Brazil authorizes Butanvac vaccine for volunteers in clinical trial

BRASILIA, July 7 (Reuters) – Brazilian health regulator Anvisa on Wednesday gave the go-ahead for the Butanvac COVID-19 vaccine developed by Sao Paulo’s Butantan Institute biomedical center to be used on volunteers in clinical trials.

Anvisa in a statement said the vaccine will be applied in two doses, 28 days apart. Phase I of Butanvac’s clinical trial will involve 400 volunteers, and the first two phases are expected to involve 6,000 volunteers in total.

By Jamie McGeever via Reuters

Read full article here

Share This

Chamber Updates Stay connected with Chamber activities